Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

In the present study, we evaluated the efficacy and safety of rituximab in combination with standard doxorubicin, bleomycin, vinblastine, and dacarbazine (RABVD) in patients with classical Hodgkin lymphoma (cHL). In this phase 2 study, patients with chemotherapy-naive, advanced-stage cHL were treate...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Younes, Anas, Oki, Yasuhiro, McLaughlin, Peter, Copeland, Amanda R., Goy, Andre, Pro, Barbara, Feng, Lei, Yuan, Ying, Chuang, Hubert H., Macapinlac, Homer A., Hagemeister, Fredrick, Romaguera, Jorge, Samaniego, Felipe, Fanale, Michelle A., Dabaja, Bouthaina Shbib, Rodriguez, Maria A., Dang, Nam, Kwak, Larry W., Neelapu, Sattva S., Fayad, Luis E.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Hematology 2012
Θέματα:
Clinical Trials and Observations
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3359733/
https://ncbi.nlm.nih.gov/pubmed/22371887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-01-405456
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια